Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Via Pharmaceuticals, a biotechnology company, has received a new US patent, covering the use of the company's lead compound, VIA-2291, for the treatment of atherosclerosis. This patent is also pending in other major markets worldwide.
Subscribe to our email newsletter
VIA-2291, which is currently in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets inflammation in the blood vessel wall, an underlying cause of atherosclerosis.
Lawrence Cohen, CEO of Via Pharmaceuticals, said: “This patent is an important step in the commercial development of the compound by providing Via with exclusivity in this very large and underserved market through 2026. We are pleased with the issuance of this important patent as it further strengthens and builds on our existing intellectual property protection for our lead clinical compound.”